Objective To evaluate the clinical efficiency of argon-helium cryoablation for prostate cancer. Methods The ENDOCARE cryosurgical system with 2mm Cryoprobes was used to treat the prostate cancer guided by transrectal ultrasound or abdomen ultrasound in 26 patients with a mean age of 73.2 (ranging from 65 to 89) years in our department from 1990 to 2012. Biopsy of the prostate was carried out under the guide of ultrasound at 1 and 3 months after cryotherapy for pathological observation. Results The patients were all followed up for 3 to 24 months. The biopsy results showed that 19 cases were pathologically negative and 7 cases were positive. The obstructions of bladder outlet were all relieved, and hematuria was attenuated or disappeared. Serum prostatic specific antigen (PSA) level was decreased obviously. Bone metastases partially disappeared or shrunk. Bone pain was relieved to some extent. Twenty of them were able to urinate. All patients had their serum levels of PSA lower than 4ng/ml at 3 to 24 months after cryoablation. Conclusion Cryoablation combined with anti-androgen drug has better clinical outcome in the treatment of prostate cancer, with advantages of short hospitalization period, no blood loss, little injury and rapid recovery.